Total Payments
$4,905
2024 Payments
$804.51
Companies
52
Transactions
229
Medicare Patients
11,889
Medicare Billing
$10.6M
Payment Breakdown by Category
Food & Beverage$4,818 (98.2%)
Education$86.69 (1.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,818 | 223 | 98.2% |
| Education | $86.69 | 6 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| McKesson Specialty Care Distribution, LLC | $403.00 | 4 | $0 (2020) |
| Janssen Biotech, Inc. | $368.61 | 23 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $338.20 | 22 | $0 (2023) |
| Merck Sharp & Dohme LLC | $319.72 | 18 | $0 (2024) |
| ABBVIE INC. | $276.15 | 12 | $0 (2024) |
| Gilead Sciences, Inc. | $243.04 | 3 | $0 (2023) |
| Genentech USA, Inc. | $205.40 | 11 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $198.68 | 8 | $0 (2024) |
| Astellas Pharma US Inc | $178.50 | 10 | $0 (2023) |
| Daiichi Sankyo Inc. | $169.13 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $804.51 | 34 | ABBVIE INC. ($225.50) |
| 2023 | $1,218 | 50 | Gilead Sciences, Inc. ($231.12) |
| 2022 | $520.07 | 22 | Daiichi Sankyo Inc. ($100.00) |
| 2021 | $66.83 | 5 | GENZYME CORPORATION ($18.26) |
| 2020 | $221.42 | 10 | McKesson Specialty Care Distribution, LLC ($58.27) |
| 2019 | $833.25 | 37 | McKesson Specialty Care Distribution, LLC ($344.73) |
| 2018 | $614.81 | 39 | Janssen Biotech, Inc. ($91.16) |
| 2017 | $626.28 | 32 | Sirtex Medical Inc ($115.27) |
All Payment Transactions
229 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: DESMOID TUMORS | ||||||
| 11/08/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Rare Disease | ||||||
| 10/02/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $28.07 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Immunology | ||||||
| 08/14/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $28.37 | General |
| Category: Oncology | ||||||
| 07/26/2024 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/19/2024 | Genentech USA, Inc. | Alecensa (Biological), Rozlytrek, Tecentriq | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: BioOncology | ||||||
| 07/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: Oncology | ||||||
| 07/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.32 | General |
| Category: Oncology | ||||||
| 05/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: Oncology | ||||||
| 05/01/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: ONCOLOGY | ||||||
| 04/21/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | Genentech USA, Inc. | Alecensa (Biological), Phesgo, Rozlytrek | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,730 | 128,794 | $8.0M | $2.6M |
| 2022 | 46 | 2,772 | 141,752 | $8.1M | $2.6M |
| 2021 | 53 | 3,065 | 293,867 | $9.9M | $3.0M |
| 2020 | 50 | 3,322 | 269,484 | $7.3M | $2.3M |
Total Patients
11,889
Total Services
833,897
Medicare Billing
$10.6M
Procedure Codes
199
All Medicare Procedures & Services
199 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 25 | 34,200 | $3.8M | $1.5M | 39.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 83 | 18,420 | $810,480 | $335,664 | 41.4% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 12 | 5,150 | $566,500 | $180,837 | 31.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 75 | 9,700 | $630,500 | $159,729 | 25.3% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 11 | 3,020 | $543,600 | $106,254 | 19.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 116 | 701 | $368,025 | $71,685 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 421 | 755 | $126,902 | $49,009 | 38.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 203 | 450 | $117,000 | $43,880 | 37.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 15,200 | $152,000 | $34,929 | 23.0% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 420 | $189,000 | $29,858 | 15.8% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 21 | 66 | $87,450 | $22,904 | 26.2% |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 2023 | 12 | 18,120 | $36,240 | $13,845 | 38.2% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 14 | 1,420 | $113,600 | $11,134 | 9.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 496 | 1,470 | $39,690 | $11,111 | 28.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 15 | 60 | $33,000 | $10,772 | 32.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 39 | 207 | $51,750 | $10,467 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 60 | 60 | $32,640 | $10,370 | 31.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 103 | 196 | $46,060 | $9,725 | 21.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 71 | 417 | $49,206 | $9,320 | 18.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 148 | 544 | $32,640 | $5,961 | 18.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 28 | 176 | $22,176 | $4,712 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 34 | $12,784 | $4,567 | 35.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 71 | 370 | $30,340 | $4,416 | 14.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 55 | 55 | $4,950 | $3,935 | 79.5% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 19 | 90 | $19,620 | $3,927 | 20.0% |
About Dr. Jonathan Bender, M.D
Dr. Jonathan Bender, M.D is a Hematology & Oncology healthcare provider based in Fayetteville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649228651.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Bender, M.D has received a total of $4,905 in payments from pharmaceutical and medical device companies, with $804.51 received in 2024. These payments were reported across 229 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($4,818).
As a Medicare-enrolled provider, Bender has provided services to 11,889 Medicare beneficiaries, totaling 833,897 services with total Medicare billing of $10.6M. Data is available for 4 years (2020–2023), covering 199 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fayetteville, GA
- Active Since 05/04/2006
- Last Updated 07/02/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1649228651
Products in Payments
- KEYTRUDA (Biological) $260.04
- Trodelvy (Drug) $231.12
- DARZALEX (Biological) $206.78
- IMBRUVICA (Drug) $202.08
- LIBTAYO (Biological) $198.68
- VENCLEXTA (Drug) $197.19
- Orserdu (Drug) $128.89
- SIR-Spheres Microspheres (Device) $115.27
- ENHERTU (Drug) $100.00
- MEKINIST (Drug) $96.15
- NINLARO (Drug) $95.28
- XTANDI (Drug) $93.39
- SPRYCEL (Drug) $76.47
- Braftovi (Drug) $65.12
- ELIQUIS (Drug) $61.90
- GAZYVA (Biological) $59.88
- XARELTO (Drug) $58.31
- EPKINLY (Drug) $57.84
- Neulasta (Biological) $55.31
- JADENU (Drug) $55.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fayetteville
Dr. Eric Schaefer, M.d, M.D
Hematology & Oncology — Payments: $343,754
Hematology & Oncology $343,754
Trevor Feinstein, M.d, M.D
Hematology & Oncology — Payments: $293,737
Hematology & Oncology $293,737
Dr. J Beck, M.d., F.a.c.p, M.D., F.A.C.P
Hematology & Oncology — Payments: $181,928
Hematology & Oncology $181,928
Dr. Patrick Travis, M.d, M.D
Hematology & Oncology — Payments: $69,474
Hematology & Oncology $69,474
Dr. Stephan Rosenfeld, M.d, M.D
Hematology & Oncology — Payments: $63,644
Hematology & Oncology $63,644
Dr. Tariq Nazir, M.d, M.D
Hematology & Oncology — Payments: $60,775
Hematology & Oncology $60,775